Potentially active compounds that improve PAD through angiogenesis: A review - 11/11/23
Abstract |
Peripheral arterial disease (PAD) has been historically neglected, which has resulted in a lack of effective drugs in clinical practice. However, with the increasing prevalence of diseases like atherosclerosis and diabetes, the incidence of PAD is rising and cannot be ignored. Researchers are exploring the potential of promoting angiogenesis through exogenous compounds to improve PAD. This paper focuses on the therapeutic effect of natural products (Salidroside, Astragaloside IV, etc.) and synthetic compounds (Cilostazol, Dapagliflozin, etc.). Specifically, it examines how they can promote autocrine secretion of vascular endothelial cells, enhance cell paracrine interactions, and regulate endothelial progenitor cell function. The activation of these effects may be closely related to PI3K, AMPK, and other pathways. Overall, these exogenous compounds have promising therapeutic potential for PAD. This study aims to summarize the potential active compounds, provide a variety of options for the search for drugs for the treatment of PAD, and bring light to the treatment of patients.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | To summarize the natural products and synthetic compounds with potential therapeutic effects on PAD in recent years. |
• | Certain natural products and synthetic compounds can stimulate angiogenesis through autocrine, paracrine, and endothelial progenitor cells. |
• | Natural products and synthetic compounds are involved in multiple signaling pathways to improve PAD. |
Chemical compounds studied in this article : Astragaloside IV (PubChem CID:13943297), Ginsenoside Rg5 (PubChem CID:11550001), Aucubin (PubChem CID:91458), Caffeine (PubChem CID:2519), Liraglutide (PubChem CID:16134956), Resveratrol (PubChem CID:445154), 20(S)-protopanaxadiol (PubChem CID:11213350), Apabetalone (PubChem CID:135564749), Oroxylin A (PubChem CID:5320315), Salidroside (PubChem CID:159278), Cilostazol (PubChem CID:2754), Dapagliflozin (PubChem CID:9887712), Empagliflozin (PubChem CID:11949646), Naringin (PubChem CID:442428), Quercetin (PubChem CID:5280343), Bavachalcone (PubChem CID:6450879) Sitagliptin (PubChem CID:4369359), Rivaroxaban(PubChem CID:9875401), Curcumin (PubChem CID:969516)
Abbreviations : PAD, CLI, HLI, VECs, eNOS, AS-IV, EPCs, IGF-1R, AU, MFF, Drp1, GLP-1, Lira, HO-1, SIRT1, FOXO1, RSV, PPD, BRD4, APA, BET, KLX, OA, TBX20, PROK2, RhoA, ROCK-II, PHD3, PPAR, SGLT2, EPO, BavaC, Nrf2, RORα, THBS1
Keywords : PAD, Natural products, Synthetic compounds, Angiogenesis, Hindlimb ischemia, Diabetes
Plan
Vol 168
Article 115634- décembre 2023 Retour au numéro
Article précédent
- Ferroptosis in cardiac hypertrophy and heart failure
- Kuo Zhang, Xin-Miao Tian, Wei Li, Li-Ying Hao
- Disco interacting protein 2 homolog A (DIP2A): A key component in the regulation of brain disorders
- Baoyuan Zhang, Xuesong Zhang, Moussa Omorou, Kai Zhao, Yang Ruan, Haiyan Luan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?